The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CNTB | +131.43% | N/A | N/A | +22% |
| S&P | +13.95% | +78.35% | +12.25% | +8% |
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. It focuses on advancing rademikibart, an anti-interleukin-4-receptor alpha antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in San Diego, CA.
No news articles found for Connect Biopharma.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $16.00K | 0.0% |
| Gross Profit | -$173.00K | 0.0% |
| Market Cap | $84.14M | 0.0% |
| Net Income | -$17,200.00K | 0.0% |
| EBITDA | -$17,498.00K | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $37.85M | 0.0% |
| Accounts Receivable | $17.00K | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $445.00K | 0.0% |
| Short Term Debt | $336.00K | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | -59.57% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$17,732.54K | 0.0% |
| Operating Free Cash Flow | -$17,695.95K | 0.0% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|
| Price to Book | 0.33 | 0.65 | 1.18 | - |
| Price to Tangible Book Value | 0.33 | 0.65 | 1.18 | - |
| Enterprise Value to EBITDA | 4.67 | 1.25 | -1.72 | - |
| Total Debt | $940.00K | $870.00K | $781.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
